ENMD-2076 for hematological malignancies

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.21, Iss.5, 2012-05, pp. : 717-732

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma

By Zhang Shuhong Farag Sherif S

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 7, 2011-07 ,pp. : 1015-1028

Informa Healthcare

Access to resources Recommend Favorite

Novel Immunotherapies for Hematological Malignancies

Current Molecular Pharmacology, Vol. 9, Iss. 3, 2016-09 ,pp. : 264-271

Bentham Science Publishers

Access to resources Recommend Favorite

The Immunoproteasome as a Therapeutic Target for Hematological Malignancies

Current Cancer Drug Targets, Vol. 14, Iss. 6, 2014-07 ,pp. : 537-548

Bentham Science Publishers

Access to resources Recommend Favorite

Corticoisteroid-Induced Apoptosis in Hematological Malignancies

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents), Vol. 8, Iss. 1, 2009-03 ,pp. : 38-46

Bentham Science Publishers

Access to resources Recommend Favorite

Epigenetically - Targeted Therapies for the Treatment of Hematological Malignancies

Current Medicinal Chemistry, Vol. 18, Iss. 12, 2011-04 ,pp. : 1757-1764

Bentham Science Publishers

Access to resources Recommend Favorite